Last reviewed · How we verify
Idiopathic short stature in pediatric patients 2 years of age and older
Approved treatments
- NGENLA (Somatrogon) · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Idiopathic short stature in pediatric patients 2 years of age and older patent landscape — cliff calendar, originator estates, attackable patents
- Idiopathic short stature in pediatric patients 2 years of age and older treatment landscape brief
- Idiopathic short stature in pediatric patients 2 years of age and older treatment updates RSS
Frequently asked questions about Idiopathic short stature in pediatric patients 2 years of age and older
What drugs treat Idiopathic short stature in pediatric patients 2 years of age and older?
Tracked treatments include NGENLA (Somatrogon).
What is the treatment for Idiopathic short stature in pediatric patients 2 years of age and older?
Standard treatment for Idiopathic short stature in pediatric patients 2 years of age and older includes NGENLA (Somatrogon). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Idiopathic short stature in pediatric patients 2 years of age and older patent cliff · Idiopathic short stature in pediatric patients 2 years of age and older CI report
- Treatment: NGENLA (Somatrogon) · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing